Overview

Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic bone marrow transplantation in treating patients who have multiple myeloma, chronic phase chronic myelogenous leukemia, or agnogenic myeloid metaplasia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Northwestern University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Busulfan
Cyclophosphamide
Criteria
DISEASE CHARACTERISTICS:

- Cytologically proven disease of one of the following types with transfusion-dependent
anemia or thrombocytopenia (less than 50,000/mm^3):

- Multiple myeloma

- Agnogenic myeloid metaplasia

- Chronic myelogenous leukemia in first or second chronic phase

- Philadelphia chromosome with BCR gene rearrangement

- Suitable sibling bone marrow donor available

PATIENT CHARACTERISTICS:

Age:

- 15 to physiologic 55

Performance status:

- ECOG 0 or 1

Life expectancy:

- Not specified

Hematopoietic:

- See Disease Characteristics

Hepatic:

- Bilirubin no greater than 2.0 mg/dL

- SGOT less than 2 times normal

- Alkaline phosphatase less than 2 times normal

Renal:

- Creatinine less than 2 mg/dL

Cardiovascular:

- Ejection fraction normal by MUGA

- No acute myocardial infarction within the past 6 months

- No active angina pectoris

- No active congestive heart failure

Pulmonary:

- FEV greater than 50% predicted

- DLCO at least 50%

Other:

- HIV negative

- No active infection

- No concurrent organ damage or medical problems that would preclude therapy

PRIOR CONCURRENT THERAPY:

- Not specified